Your browser doesn't support javascript.
loading
Reprogramming T-Cell Metabolism for Better Anti-Tumor Immunity.
Ping, Yu; Shen, Chunyi; Huang, Bo; Zhang, Yi.
Afiliación
  • Ping Y; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
  • Shen C; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
  • Huang B; Department of Immunology & National Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College, Beijing 100005, China.
  • Zhang Y; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Cells ; 11(19)2022 10 01.
Article en En | MEDLINE | ID: mdl-36231064
T cells play central roles in the anti-tumor immunity, whose activation and differentiation are profoundly regulated by intrinsic metabolic reprogramming. Emerging evidence has revealed that metabolic processes of T cells are generally altered by tumor cells or tumor released factors, leading to crippled anti-tumor immunity. Therefore, better understanding of T cell metabolic mechanism is crucial in developing the next generation of T cell-based anti-tumor immunotherapeutics. In this review, we discuss how metabolic pathways affect T cells to exert their anti-tumor effects and how to remodel the metabolic programs to improve T cell-mediated anti-tumor immune responses. We emphasize that glycolysis, carboxylic acid cycle, fatty acid oxidation, cholesterol metabolism, amino acid metabolism, and nucleotide metabolism work together to tune tumor-reactive T-cell activation and proliferation.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Neoplasias Límite: Humans Idioma: En Revista: Cells Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Neoplasias Límite: Humans Idioma: En Revista: Cells Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza